VP
Insider
Venrock Healthcare Capital Partners III, L.P.
10% ownerVenrock Healthcare Capital Partners III, L.P. (10% owner) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 0 sales), most often in Lycia Therapeutics, Inc. (LYCA). The largest single filing was $37.7M of LYCA (2,045,440 sh across 6 lots, as filed), executed Oct 23. The median gap between execution and disclosure was 2 days. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
purchases not yet priced
Delay-adjustediThe same average, entered at disclosure dates
–
purchases not yet priced
Filings, ttm
3
3 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$38.5M
shares × price, as filed
Last traded
Nov 2
Filed Nov 4
Median ADV $42.4M across their filed names
100% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Open performance→Volume by month
Buys $39.4M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
LYCARecent filings
LYCAPURCHASE
Lycia Therapeutics, Inc.
View filing →
$224K8,305 sh × $26.95
Exec Nov 2
Filed Nov 4 · 5:12 PM ET LYCAPURCHASE Lycia Therapeutics, Inc. View filing → $613K
23,804 sh across 3 lots
Exec Oct 28
Filed Oct 30 · 7:25 PM ET LYCAPURCHASE Lycia Therapeutics, Inc. View filing → $37.7M
2,045,440 sh across 6 lots
Exec Oct 23
Filed Oct 27 · 6:38 PM ET KALVPURCHASE KalVista Pharmaceuticals, Inc. View filing → $929K
100,352 sh across 2 lots
Exec Feb 7 2025
Filed Feb 11 2025 · 5:30 PM ET